BPOM Head Taruna Ikrar said the antibacterial drug, developed by Australia's Recce Pharmaceuticals, targets sepsis-causing pathogens and is designed to prevent antibiotic resistance.
"The product is a novel synthetic antibiotic. We welcome its development in Indonesia, especially given the growing global concern over resistance," Ikrar said in a statement on Friday.
In Australia, BPOM held talks with representatives from Investment New South Wales, Austrade, and Recce Pharmaceuticals. The drug's development in Indonesia will be carried out in partnership with local firm PT Etana Biotechnologies Indonesia through a new drug development scheme, he said.
Ikrar said BPOM is committed to facilitating the introduction of innovative pharmaceutical products that align with national health priorities.
Collaborative efforts from regulators and stakeholders are necessary to ensure the availability of new medicines for people, he added.
Hence, BPOM consistently pursues effectiveness and efficiency in their clinical trial issuance by establishing a clear legal basis and mechanisms to facilitate pharmaceutical industries, he noted.
The clear, transparent, adaptive policies are expected to attract sponsors, both domestically and globally, so they are interested in developing products in Indonesia, he pointed out.
"I hope this innovative product from Recce can develop as a product available in Indonesia and have a tangible impact on people," he noted.
Meanwhile, Managing Director and Chief Executive Officer of Recce James Graham was quoted as saying that their collaboration with Etana for the technology transfer in the antibacterial product is the first ever in Indonesia.
Graham expects that through their collaboration, their first product can be available in Indonesia by 2026.
Indonesia will be the first to use the new anti-infection liquid product for diabetic foot injection (DFI) patients, he was quoted as saying in the statement.
Related news: RI, Australia forge strategic partnership for health transformation
Reporter: Mecca Yumna Ning Prisie
Editor: Rahmad Nasution
Copyright © ANTARA 2025
